Gliclazide and Nadolol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Nadolol (nadolol). Common drug interactions include atypical femur fracture among females and bacteraemia among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Nadolol. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Nadolol?

Nadolol has active ingredients of nadolol. It is often used in high blood pressure. eHealthMe is studying from 4,476 Nadolol users. Check the latest studies of Nadolol.

On Jul, 08, 2026

13 people who take Gliclazide and Nadolol together, and have interactions are studied.

Gliclazide and Nadolol drug interactions.

What are the common drug interactions of Gliclazide and Nadolol, by gender? *:

female:

Atypical femur fracture
Humerus fracture (injury to the upper arm bone)
Arthralgia (joint pain)
Back pain
Cellulitis (infection under the skin)
Death
Dysuria (painful or difficult urination)
Escherichia sepsis (bacterial infection by escherichia coli)
Heart rate decreased
Hypotension (abnormally low blood pressure)

male:

Bacteraemia (presence of bacteria in the blood)
Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Atrioventricular block (heart block)
Headache (pain in head)
Hypersensitivity
Cerebellar syndrome (impaired blood circulation to cerebellum due to lesion in artery)
Chorioretinitis (an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye)
Hepatotoxicity (chemical-driven liver damage)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Pneumonia klebsiella (pneumonia caused by bacteria klebsiella)

What are the common drug interactions of Gliclazide and Nadolol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Bacteraemia (presence of bacteria in the blood)
Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Cerebellar syndrome (impaired blood circulation to cerebellum due to lesion in artery)
Chorioretinitis (an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye)
Hepatotoxicity (chemical-driven liver damage)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Pneumonia klebsiella (pneumonia caused by bacteria klebsiella)
Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)
Systemic candida (whole body fungal infection)
Atypical femur fracture

60+:

Loss of consciousness
Arthralgia (joint pain)
Weight increased
Atrioventricular block (heart block)
Back pain
Dysuria (painful or difficult urination)
Escherichia sepsis (bacterial infection by escherichia coli)
Headache (pain in head)
Hypersensitivity
Hypotension (abnormally low blood pressure)

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 5 people, 38.46%
Osteoporosis (bones weak and more likely to break): 3 people, 23.08%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 7.69%
Quit Smoking: 1 person, 7.69%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 7.69%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 7.69%
Interstitial Lung Disease: 1 person, 7.69%
Gout (uric acid crystals building up in the body): 1 person, 7.69%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 7.69%
Cardiac Failure Congestive: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Nadolol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously